Search Results

Cardea Bio, Inc. reaches an 8-year milestone of the first external partner starting to use the BPU platform for advancing drug discovery research to produce new and highly sought-after insights.

Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, has been named a finalist in the 2022 Fierce Healthcare Innovation Awards for its Cardea SOLO™ ECG System.

As part of the Semiconductor Research Corporation (SRC) being selected by NIST’s Advanced Manufacturing Office to define the future of Microelectronics and Advanced Packaging Technology (MAPT), Cardea Bio has been invited as a commercial semiconductor company to share their experience with integrating biology with electronics.

Cardiac Insight, Inc. announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score The study set out to measure asymptomatic atrial fibrillation in older women since AF is associated with an increased risk of stroke.

Today, Cardea Bio, Inc. announced a collaboration agreement with Siemens Healthineers’ Center for Innovation in Diagnostics (CID) to assess feasibility of developing real-time biosensor applications using Cardea’s BPU™ (Biosignal Processing Unit) Platform.

Dr. Kiana Aran, recently received a Research Gift from Agilent Technologies’ university relations program to support her research on developing a scalable detection platform to continuously monitor the quality and health of cell cultures using Cardea’s graphene-based BPU™ (Biosignal Processing Unit) platform.

CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, that may serve as a lead-in to its Phase 3 development program of Auxora™ in patients with critical COVID-19 pneumonia.

Cardea Bio, a Tech+Bio company that has integrated molecular biology with semiconductor electronics, today announced that Dawn Barry has joined the company’s Board of Directors.

Cardea, a complete open-source ecosystem for the exchange of privacy-preserving digital health credentials has been accepted as a Linux Foundation Public Health project.

CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the results from CARDEA, a Phase 2 trial of its lead drug candidate Auxora™ in patients with severe COVID-19 pneumonia.